Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria

Bioorganic and Medicinal Chemistry Letters

Volumn 27, Issue 11, 2017, Pages 2407-2409

  Becker, Bernd ^a   Butler, Mark S ^a   Hansford, Karl A ^a   Gallardo Godoy, Alejandra ^a   Elliott, Alysha G ^a   Huang, Johnny X ^a   Edwards, David J ^a   Blaskovich, Mark A T ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibiotic; Colistin; Drug resistance; Lipopeptide; Natural product

Indexed keywords

ANTIBIOTIC AGENT; OCTAPEPTIN C4; POLYMYXIN B; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; LIPOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; KIDNEY CELL LINE; KIDNEY TUBULE CELL; MULTIDRUG RESISTANCE; NONHUMAN; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS AUREUS; CYCLIZATION; DRUG EFFECTS; SYNTHESIS;

ANTI-BACTERIAL AGENTS; CYCLIZATION; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; LIPOPEPTIDES; PEPTIDES, CYCLIC; POLYMYXIN B; SOLID-PHASE SYNTHESIS TECHNIQUES; STAPHYLOCOCCUS AUREUS;

EID: 85018936763     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2017.04.027     Document Type: Article

References (24)

1. 1 O'Neill J. UK Review on Antimicrobial Resistance. Tackling Drug-resistant Infections Globally: an overview of our work Jan 2016; 2016. https://amr-review.org/sites/default/files/Tackling%20drug-resistant%20infections%20-%20An%20overview%20of%20our%20work_IncHealth_LR_NO%20CROPS.pdf.
2. 2 Reardon, S., Antibiotic resistance sweeping developing world. Nature 509 (2014), 141–142.
3. 3 Sprenger, M., Fukuda, K., New mechanisms, new worries. Science 351 (2016), 1263–1264.
4. 4 Butler, M.S., Blaskovich, M.A.T., Cooper, M.A., Antibiotics in the clinical pipeline at the end of 2015. J Antibiot 70 (2017), 3–24.
5. 5 Boucher, H.W., Talbot, G.H., Bradley, J.S., et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society Of America. Clin Infect Dis 48 (2009), 1–12.
6. 6 Velkov, T., Thompson, P.E., Nation, R.L., Li, J., Structure-activity relationships of polymyxin antibiotics. J Med Chem 53 (2010), 1898–1916.
7. 7 Vaara, M., Novel derivatives of polymyxins. J Antimicrob Chemother 68 (2013), 1213–1219.
8. 8 Velkov, T., Roberts, K.D., Thompson, P.E., Li, J., Polymyxins: a new hope in combating Gram-negative superbugs?. Future Med Chem 8 (2016), 1017–1025.
9. 9 Brown, P., Dawson, M.J., Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J Antibiot, 70, 2017, 10.1038/ja.2016.1146.
10. 10 Cochrane, S.A., Vederas, J.C., Lipopeptides from Bacillus and Paenibacillus spp.: a gold mine of antibiotic candidates. Med Res Rev 36 (2016), 4–31.
11. 11 Storm, D.R., Rosenthal, K.S., Swanson, P.E., Polymyxin and related peptide antibiotics. Annu Rev Biochem 46 (1977), 723–763.
12. 12 Konishi, M., Sugawara, K., Tomita, K., et al. Bu-2470, a new peptide antibiotic complex. 1. Production, isolation and properties of Bu-2470-A, Bu -2470-B1 and Bu -2470-B2. J Antibiot 36 (1983), 625–633.
13. 13 Meyers, E., Parker, W.L., Brown, W.E., Linnett, P., Stroming, J.I., EM49 - new polypeptide antibiotic active against cell-membranes. Ann N Y Acad Sci 235 (1974), 493–501.
14. 14 Meyers, E., Brown, W.E., Principe, P.A., Rathnum, M.L., Parker, W.L., EM49 - new peptide antibiotic. 1. Fermentation, isolation, and preliminary characterization. J Antibiot 26 (1973), 444–448.
15. 15 Meyers, E., Pansy, F.E., Basch, H.I., et al. EM49 - new peptide antibiotic.3. Biological characterization in-vitro and in-vivo. J Antibiot 26 (1973), 457–462.
16. 16 Meyers, E., Parker, W.L., Brown, W.E., Shoji, J., Wakisaka, Y., Nomenclature proposal for octapeptin antibiotics. J Antibiot 29 (1976), 1241–1242.
17. 17 Parker, W.L., Rathnum, M.L., EM49, a new peptide antibiotic IV. The structure of EM49. J Antibiot 28 (1975), 379–389.
18. 18 Qian, C.-D., Wu, X.-C., Teng, Y., et al. Battacin (octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant gram-negative bacteria. Antimicrob Agents Chemother 56 (2011), 1458–1465.
19. 19 De Zoysa, G.H., Cameron, A.J., Hegde, V.V., Raghothama, S., Sarojini, V., Antimicrobial peptides with potential for biofilm eradication: synthesis and structure activity relationship studies of battacin peptides. J Med Chem 58 (2015), 625–639.
20. 20 Swanson, P.E., Paddy, M.R., Dahlquist, F.W., Storm, D.R., Characterization of octapeptin-membrane interactions using spin-labeled octapeptin. Biochemistry 19 (1980), 3307–3314.
21. 21 Pluscec, J., Sabo, E.F., Neubeck, R.O., Weaver, E.R., Basch, H., Ondetti, M.A., N-substituted derivatives of EM 49 structure-activity-relationships. J Antibiot 30 (1977), 756–758.
22. 22 Gallardo-Godoy, A., Muldoon, C., Becker, B., et al. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. J Med Chem 59 (2016), 1068–1077.
23. 23 Bollhagen, R, Schmiedberger, M, Barlosb, K, Grell, E., A new reagent for the cleavage of fully protected peptides synthesised on 2-chlorotrityl chloride resin. J Chem Soc, Chem Comm, 1994, 2559–2560.
24. 24 Huang, JX, Kaeslin, G, Ranall, MV, et al. Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol Res Perspect, 2015, 3, 10.1002/prp1002.1148.